Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Rachel

Showing results (121-130 of 133) with videos related to

Pageof 14
Sort By:
International Journal of Cancer|December 22, 2015
Progression of HPV infection to detectable cervical lesions or clearance in adult women: Analysis of the control arm of the VIVIANE studyS Rachel Skinner, Cosette M Wheeler, Barbara Romanowski, et al.
The Lancet. Oncology|November 15, 2011
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trialCosette M Wheeler, Xavier Castellsagué, Suzanne M Garland, et al.
Gynecologic Oncology|September 4, 2012
Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women at enrolment in the multinational PATRICIA trialEdith Roset Bahmanyar, Jorma Paavonen, Paulo Naud, et al.
Clinical and Vaccine Immunology : CVI|February 6, 2015
Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trialDan Apter, Cosette M Wheeler, Jorma Paavonen, et al.
BMC Infectious Diseases|May 1, 2015
Risk of first cervical HPV infection and pre-cancerous lesions after onset of sexual activity: analysis of women in the control arm of the randomized, controlled PATRICIA trialXavier Castellsagué, Jorma Paavonen, Unnop Jaisamrarn, et al.
Lancet (London, England)|September 6, 2014
Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE studyS Rachel Skinner, Anne Szarewski, Barbara Romanowski, et al.
The Journal of Infectious Diseases|October 5, 2013
Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observationAnne Szarewski, S Rachel Skinner, Suzanne M Garland, et al.
The Journal of Infectious Diseases|March 11, 2014
Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control arm of PATRICIAXavier Castellsagué, Paulo Naud, Song-Nan Chow, et al.
Plos One|November 22, 2013
Natural history of progression of HPV infection to cervical lesion or clearance: analysis of the control arm of the large, randomised PATRICIA studyUnnop Jaisamrarn, Xavier Castellsagué, Suzanne M Garland, et al.
The Lancet. Oncology|November 15, 2011
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trialMatti Lehtinen, Jorma Paavonen, Cosette M Wheeler, et al.
Pageof 14

Showing results (121-130 of 133) with videos related to

Sort By:
Pageof 14
International Journal of Cancer|December 22, 2015
Progression of HPV infection to detectable cervical lesions or clearance in adult women: Analysis of the control arm of the VIVIANE studyS Rachel Skinner, Cosette M Wheeler, Barbara Romanowski, et al.
The Lancet. Oncology|November 15, 2011
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trialCosette M Wheeler, Xavier Castellsagué, Suzanne M Garland, et al.
Gynecologic Oncology|September 4, 2012
Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women at enrolment in the multinational PATRICIA trialEdith Roset Bahmanyar, Jorma Paavonen, Paulo Naud, et al.
Clinical and Vaccine Immunology : CVI|February 6, 2015
Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trialDan Apter, Cosette M Wheeler, Jorma Paavonen, et al.
BMC Infectious Diseases|May 1, 2015
Risk of first cervical HPV infection and pre-cancerous lesions after onset of sexual activity: analysis of women in the control arm of the randomized, controlled PATRICIA trialXavier Castellsagué, Jorma Paavonen, Unnop Jaisamrarn, et al.
Lancet (London, England)|September 6, 2014
Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE studyS Rachel Skinner, Anne Szarewski, Barbara Romanowski, et al.
The Journal of Infectious Diseases|October 5, 2013
Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observationAnne Szarewski, S Rachel Skinner, Suzanne M Garland, et al.
The Journal of Infectious Diseases|March 11, 2014
Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control arm of PATRICIAXavier Castellsagué, Paulo Naud, Song-Nan Chow, et al.
Plos One|November 22, 2013
Natural history of progression of HPV infection to cervical lesion or clearance: analysis of the control arm of the large, randomised PATRICIA studyUnnop Jaisamrarn, Xavier Castellsagué, Suzanne M Garland, et al.
The Lancet. Oncology|November 15, 2011
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trialMatti Lehtinen, Jorma Paavonen, Cosette M Wheeler, et al.
Pageof 14